{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:52:25Z","timestamp":1771462345218,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermer\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.enfcli.2017.03.010","type":"journal-article","created":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T17:59:50Z","timestamp":1510855190000},"page":"361-368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Mejora de la calidad de vida de los pacientes con urticaria cr\u00f3nica espont\u00e1nea tratados con omalizumab en vida real"],"prefix":"10.1016","volume":"27","author":[{"given":"Itz\u00edar","family":"Larrea-Baca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Gurpegui-Resano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.enfcli.2017.03.010_bib0145","first-page":"80","article-title":"Assessment of severity and quality of life in chronic urticaria","volume":"24","author":"Jauregui","year":"2014","journal-title":"J Investig Allergol Clin Imnunol."},{"key":"10.1016\/j.enfcli.2017.03.010_bib0150","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","article-title":"Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report","volume":"66","author":"Maurer","year":"2011","journal-title":"Allergy."},{"key":"10.1016\/j.enfcli.2017.03.010_bib0155","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jaci.2011.04.038","article-title":"Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase","volume":"128","author":"Maurer","year":"2011","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.enfcli.2017.03.010_bib0160","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1046\/j.1398-9995.2003.00327.x","article-title":"Urticaria","volume":"58","author":"Zuberbier","year":"2003","journal-title":"Allergy."},{"key":"10.1016\/j.enfcli.2017.03.010_bib0165","first-page":"54","article-title":"Urticaria y angioedema","volume":"54","author":"Guillen Escal\u00f3n","year":"2007","journal-title":"Revista Alergia M\u00e9xico."},{"key":"10.1016\/j.enfcli.2017.03.010_bib0170","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/all.12313","article-title":"Gu\u00eda EAACI\/GA2LEN\/EDF\/WAO para la definici\u00f3n, clasificaci\u00f3n, diagn\u00f3stico y manejo de la urticaria: revisi\u00f3n y actualizaci\u00f3n de 2013","volume":"69","author":"Zuberbier","year":"2013","journal-title":"Allergy."},{"key":"10.1016\/j.enfcli.2017.03.010_bib0175","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1398-9995.2009.02178.x","article-title":"EAACI\/GA2LEN\/EDF\/WAO guideline: management of urticaria","volume":"64","author":"Zuberbier","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.enfcli.2017.03.010_bib0180","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJMcp011186","article-title":"Clinical Practice. Chronic Urticarial and Angioedema","volume":"346","author":"Kaplan","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.enfcli.2017.03.010_bib0185","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/j.1398-9995.2011.02695.x","article-title":"Crosscultutal adaptation of the Brazilian-Portuguese version of the chronic urticaria qualityof-life questionnaire- CU-Q2oL","volume":"66","author":"Dias","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.enfcli.2017.03.010_bib0190","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1385\/CRIAI:23:2:147","article-title":"An overview of chronic urticarial","volume":"23","author":"Beltrani","year":"2002","journal-title":"Clin Rev Allergy Immunol."},{"key":"10.1016\/j.enfcli.2017.03.010_bib0195","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2133.1997.tb14895.x","article-title":"The impact of chronic urticaria on the quality of life","volume":"136","author":"O\u2019Donnell","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.enfcli.2017.03.010_bib0200","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1034\/j.1398-9995.2003.00091.x","article-title":"Quality of life and patients satisfaction in chronic urticaria and respiratory allergy","volume":"58","author":"Baiardini","year":"2003","journal-title":"Allergy."},{"key":"10.1016\/j.enfcli.2017.03.010_bib0205","first-page":"180","article-title":"Correlaci\u00f3n de la gravedad de la urticaria cr\u00f3nica y la calidad de vida","volume":"59","author":"Aguilar-Hinijosa","year":"2012","journal-title":"Revista Alergia M\u00e9xico."},{"key":"10.1016\/j.enfcli.2017.03.010_bib0210","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hup.1184","article-title":"Brain histamine H1 receptor occupancy of loratadine measured by positr\u00f3n emission topography: comparison of H1 receptor occupancy and proportional impairment ratio","volume":"26","author":"Kubo","year":"2011","journal-title":"Hum Psychopharmacol."},{"key":"10.1016\/j.enfcli.2017.03.010_bib0215","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2340\/00015555-1434","article-title":"Can ondemand nonsedating antihitamines improve urtiarial symptons? A doubl\u00e9-blind, randomized, single-dose study","volume":"93","author":"Weller","year":"2013","journal-title":"Acta Derm Venerol."},{"key":"10.1016\/j.enfcli.2017.03.010_bib0220","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1398-9995.2010.02472.x","article-title":"Omalizumab an effective and safe treatment of therapyresistant chronic spontaneous urticaria","volume":"66","author":"Groffik","year":"2011","journal-title":"Allergy."},{"key":"10.1016\/j.enfcli.2017.03.010_bib0225","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1081-1206(10)60644-8","article-title":"Effect of Omalizumab on patients with Chronic Urticaria","volume":"99","author":"Spector","year":"2007","journal-title":"Ann Allergy Asthma Immunol."},{"key":"10.1016\/j.enfcli.2017.03.010_bib0230","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1517\/14712598.1.6.1049","article-title":"Omalizumab, a novel anti-IgE therapy in allergic disorders","volume":"1","author":"Babu","year":"2001","journal-title":"Expert Opin Biol Ther."},{"key":"10.1016\/j.enfcli.2017.03.010_bib0235","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.enfcli.2017.03.010_bib0240","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jaci.2008.07.006","article-title":"Treatment of chronic autoimmune urticaria with omalizumab","volume":"122","author":"Kaplan","year":"2008","journal-title":"J. Allergy Clin Immunol."},{"key":"10.1016\/j.enfcli.2017.03.010_bib0245","first-page":"36","article-title":"Mitos, retos y falacias de la investigaci\u00f3n enfermera","volume":"26","author":"Amezcua","year":"2003","journal-title":"Revista Rol de Enfermer\u00eda."},{"key":"10.1016\/j.enfcli.2017.03.010_bib0250","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1213\/00000539-199809000-00045","article-title":"Statistical analysis of total labor pain using the visual analog scale and application to studies of analgesic effectiveness during childbirth","volume":"87","author":"Ludington","year":"1998","journal-title":"Anesth Analg."},{"key":"10.1016\/j.enfcli.2017.03.010_bib0255","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1398-9995.2005.00833.x","article-title":"A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-Q2oL)","volume":"60","author":"Baiardini","year":"2005","journal-title":"Allergy."},{"key":"10.1016\/j.enfcli.2017.03.010_bib0260","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1398-9995.2008.01920.x","article-title":"The German version of the chronic urticaria quality of life questionnaire. Factor analysis, validation and initial clinical findings","volume":"64","author":"Mlynek","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.enfcli.2017.03.010_bib0265","first-page":"426","article-title":"Adaptation and validation of the Spanish versin of Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL)","volume":"18","author":"Valero","year":"2008","journal-title":"J Investig Allergol Clin Immunol."},{"key":"10.1016\/j.enfcli.2017.03.010_bib0270","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1398-9995.2008.01726.x","article-title":"How to assess disease activity in patients with chronic urticaria?","volume":"63","author":"Mlynek","year":"2008","journal-title":"Allergy."},{"key":"10.1016\/j.enfcli.2017.03.010_bib0275","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1157\/13074369","article-title":"El Cuestionario de Salud SF-36 espa\u00f1ol: una d\u00e9cada de experiencia y nuevos desarrollos","volume":"19","author":"Vilagut","year":"2005","journal-title":"Gac Sanit."},{"key":"10.1016\/j.enfcli.2017.03.010_bib0280","first-page":"771","article-title":"La versi\u00f3n espa\u00f1ola del SF-36 Health Survey (Cuestionario de Salud SF-36): un instrumento para la medida de los resultados cl\u00ednicos","volume":"104","author":"Alonso","year":"1995","journal-title":"Med Clin (Barc)."}],"container-title":["Enfermer\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130862117300414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130862117300414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T13:46:50Z","timestamp":1659880010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130862117300414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1130862117300414"],"URL":"https:\/\/doi.org\/10.1016\/j.enfcli.2017.03.010","relation":{},"ISSN":["1130-8621"],"issn-type":[{"value":"1130-8621","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mejora de la calidad de vida de los pacientes con urticaria cr\u00f3nica espont\u00e1nea tratados con omalizumab en vida real","name":"articletitle","label":"Article Title"},{"value":"Enfermer\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.enfcli.2017.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}